Flow cytometry revealed reduced Gzm-B substrate cleavage in mTORC1-inhibited (rapamycin-treated) IL-2 effectors (Figure 6f), confirming a critical role for mTORC1 in regulating Gzm-B susceptibility of T-cell effectors within the tumor microenvironment. Here, IL2 is linked to neoplasm.